We are honored to share these inspirational stories from some very strong individuals.
De Soto, KS (PRWEB) November 07, 2011
Oncimmune (USA) LLC, maker of EarlyCDT®-Lung, a simple blood test that aids physicians in the early detection of lung cancer, is promoting Lung Cancer Awareness Month (LCAM) through an educational blog series. The series will feature 30 stories in 60 days from lung cancer survivors, those currently battling the disease and people who have lost loved ones to lung cancer.
Founded in 2006, Oncimmune (USA) LLC is committed to the ongoing pursuit of early cancer detection methods. Now offering the EarlyCDT-Lung test in all 50 states, Oncimmune is changing the way physicians approach lung cancer detection. EarlyCDT-Lung is a simple blood test used to identify specific autoantibodes (immuno-biomarkers), which are elevated in patients with lung cancer. Because these autoantibodies are present at the earliest stages of the disease, EarlyCDT-Lung can be used to aid in diagnosing high risk patients, potentially before they exhibit specific symptoms of lung cancer.
Observed during the month of November, LCAM is an annual educational campaign designed to raise awareness about the risk factors of lung cancer, detection methods, symptoms and available treatment options. During this annual observation, thought leaders in lung cancer research and education work together to foster conversation about this dangerous disease.
Oncimmune is doing their part to raise awareness during LCAM. The blog series was launched on Oncimmune’s educational website, http://www.HelloHaveYouHeard.com, on October 25. The 30 Stories in 60 Days series will run through mid-December. Each week the blog will feature stories of lung cancer survivors, as well as accounts from those who have lost loved ones to the disease.
One such story is of Sandra, a 66 year old lung cancer survivor. Sandra was a heavy smoker, but had stopped smoking in 2003. After suffering a continuous pain in her side, Sandra had a CT scan. The CT revealed a spot on her left lung. Her doctor recommended remaining vigilant with frequent follow-up imaging. While the spot on her lung was visible by CT, a PET scan did not reveal any signs of it being cancer.
Having lost her brother to the disease, this scare motivated Sandra to do more research. During her investigation she discovered Oncimmune’s Facebook page, and learned about EarlyCDT-Lung. Sandra decided to order an EarlyCDT-Lung collection kit and worked with her pulmonologist to have her blood drawn. The test results were positive, indicating that lung cancer might be present. After further evaluation, it turned out that Sandra had stage IA adenocarcinoma, predominantly bronchioloalveolar type.
Fortunately, her cancer had not spread to her lymph nodes and a thoracic surgeon was able to remove the tumor. In fact, just a couple weeks after Sandra’s surgery, she was back to teaching Zumba classes.
“We are honored to share these inspirational stories from some very strong individuals,” said Dan Calvo, President and CEO of Oncimmune. “Lung cancer has impacted my immediate family and I know that raising awareness about lung cancer through sharing of personal experiences is a valuable tool to fight and cope with this disease.”
In addition to the 30 Stories in 60 Days campaign, Oncimmune released an educational video series to promote LCAM. Each video provides insight and information to help the general public better understand the risks factors of lung cancer and the importance of early detection. Watch for more exciting announcements from Oncimmune as they work to educate the public about lung cancer during LCAM and throughout the year.
About Oncimmune LLC
Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. The company is committed to advancing early cancer detection through proprietary immuno-biomarker technologies based on biological technology identified by John Robertson, M.D., Professor of Surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Professor Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90% of solid-tumor cancers, which make up 70% of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. All testing is performed exclusively at Oncimmune’s CLIA (Clinical Laboratory Improvement Act) regulated laboratory located in the metro Kansas City area. Oncimmune (USA) LLC is a wholly owned subsidiary of Oncimmune LTD. Oncimmune LTD owns a portfolio of patents, including Patent Nos. 7,402,403 and 7,205,117, with five others currently filed and under review. For more information about Oncimmune, visit: http://www.hellohaveyouheard.com.